GSC Biological and Pharmaceutical Sciences

eISSN: 2581-3250 CODEN (USA): GBPSC2

Cross Ref DOI: 10.30574/gscbps

Journal homepage: https://gsconlinepress.com/journals/gscbps/

(REVIEW ARTICLE)

Formulation and Development of Transdermal Patches

Afroz Fatima * and S.S. Apte

Department of Pharmaceutical Sciences, Kakatiya University, India.

GSC Biological and Pharmaceutical Sciences, 2022, 19(01), 346–352

Publication history: Received on 18 February 2022; revised on 04 April 2022; accepted on 07 April 2022

Article DOI: https://doi.org/10.30574/gscbps.2022.19.1.0110

Abstract

Transdermal patches have emerged as a cutting-edge technology in drug delivery systems, providing a non-invasive, controlled, and patient-friendly method for administering medications. These patches deliver drugs through the skin and into the bloodstream, bypassing the gastrointestinal tract and first-pass metabolism, thereby improving bioavailability and reducing systemic side effects. This review offers an in-depth examination of the formulation and development of transdermal patches, focusing on the critical components and materials used in their construction, including active pharmaceutical ingredients, polymer matrices, permeation enhancers, adhesives, backing layers, and release liners. The development process of transdermal patches is meticulously outlined, covering stages from preformulation studies and formulation development to prototype creation, *in vivo* studies, clinical trials, regulatory approval, scale-up, and market launch. Each step is essential for ensuring the safety, efficacy, and quality of the final product. Furthermore, this review addresses the common challenges encountered in the formulation and development of transdermal patches, such as overcoming the skin's barrier properties, selecting appropriate drug candidates, ensuring proper adhesion, maintaining stability, and managing patient variability. Strategies to overcome these challenges, including the use of chemical and physical permeation enhancers, innovative adhesive technologies, and rigorous clinical testing, are discussed in detail. By providing a comprehensive overview of the formulation and development of transdermal patches, this review aims to enhance understanding of the complexities involved in creating these advanced drug delivery systems.

Keywords: Transdermal Patches; Drug Delivery; Formulation; Development Process; Challenges; Permeation Enhancers; Polymer Matrices; Adhesives

1. Introduction

Transdermal patches are a sophisticated drug delivery system designed to deliver medications through the skin directly into the bloodstream. This method offers numerous advantages over traditional routes of administration, such as oral or intravenous methods. By providing a controlled and sustained release of medication, transdermal patches ensure consistent therapeutic levels in the bloodstream, which can enhance efficacy and reduce the frequency of dosing. This method of drug delivery also bypasses the gastrointestinal tract and first-pass metabolism in the liver, resulting in improved bioavailability and reduced systemic side effects (Reddy & Guy, 2010).

1.1. Advantages of Transdermal Patches

Non-invasive Delivery: Transdermal patches provide a non-invasive alternative to injections, which can be painful and cause discomfort to patients. The non-invasive nature of transdermal patches improves patient compliance, especially for those with chronic conditions requiring long-term medication. Furthermore, it reduces the risk of infection and complications associated with needle use, making it a safer option for drug administration (Sharma & Rajput, 2018).

* Corresponding author: Afroz Fatima

Controlled and Sustained Drug Release: One of the primary advantages of transdermal patches is their ability to provide controlled and sustained drug release. This ensures that a steady amount of medication is delivered over an extended period, maintaining consistent drug levels in the bloodstream. Such a mechanism helps in avoiding the peaks and troughs of drug concentration typically associated with oral or injectable forms, thus minimizing side effects and enhancing therapeutic outcomes (Barry, 2001).

Enhanced Patient Compliance: Transdermal patches are designed for easy application and require minimal attention once applied. This ease of use significantly enhances patient compliance, as patients do not have to remember multiple doses throughout the day. Patches can be designed to last from one day to several days or even weeks, further reducing the burden on patients and improving adherence to medication regimens (Benson, 2005).

Avoidance of First-pass Metabolism: Drugs administered orally undergo first-pass metabolism in the liver, where a significant portion of the drug is metabolized before reaching systemic circulation. Transdermal delivery bypasses the gastrointestinal tract and liver, allowing the drug to enter the bloodstream directly. This bypass increases the bioavailability of the drug, often allowing for lower dosages and reducing the risk of gastrointestinal side effects associated with oral medications (Flynn, 1996).

Reduction of Systemic Side Effects: Localized delivery through the skin can minimize systemic side effects that are often seen with oral or injectable medications. By maintaining steady drug levels in the bloodstream and avoiding high peak concentrations, transdermal patches reduce the incidence of adverse effects such as nausea, dizziness, and gastrointestinal discomfort (Paudel et al., 2010).

Versatility and Flexibility: Transdermal patches can be used for a wide variety of therapeutic applications, including pain management, hormone replacement therapy, smoking cessation, cardiovascular treatment, and neurological disorders. Their versatility makes them suitable for delivering both small and large molecules, including peptides and proteins, which are typically challenging to administer via oral routes (Chien, 1992).

1.2. Applications of Transdermal Patches

Pain Management: Transdermal patches delivering analgesics such as fentanyl are widely used for chronic pain management. These patches provide continuous pain relief over several days, improving the quality of life for patients with chronic pain conditions (Gupta et al., 2012).

Hormone Replacement Therapy: Estrogen and testosterone patches are commonly prescribed for hormone replacement therapy. These patches provide consistent hormone levels, reducing the fluctuations associated with oral therapies and improving therapeutic outcomes for conditions such as menopause and hypogonadism (Ramsay & Faulkner, 2013).

Nicotine Replacement Therapy: Nicotine patches are an effective aid for smoking cessation, delivering controlled doses of nicotine to reduce withdrawal symptoms and cravings. The steady release of nicotine helps smokers gradually reduce their dependence on nicotine, facilitating the quitting process (Patel & Patel, 2019).

Cardiovascular Diseases: Transdermal patches delivering medications such as nitroglycerin are used to prevent angina pectoris. These patches provide a continuous supply of medication, ensuring consistent therapeutic effects and improving patient outcomes in cardiovascular disease management (Wiedersberg & Guy, 2014).

Neurological Disorders: Patches delivering medications for neurological conditions such as Parkinson's disease and attention deficit hyperactivity disorder (ADHD) provide sustained drug delivery, improving symptom management and patient adherence to treatment regimens (Patel et al., 2011).

2. Formulation: Key Components and Materials Used in Transdermal Patches

The formulation of transdermal patches involves a combination of active pharmaceutical ingredients (APIs) and excipients that work together to ensure effective drug delivery. Key components include:

2.1. Active Pharmaceutical Ingredients (APIs)

The selection of APIs for transdermal delivery is critical. Ideal candidates are drugs with:

- Low molecular weight (<500 Da)
- Adequate lipophilicity (Log P between 1 and 3)
- High potency, as only small amounts can permeate the skin (Karande et al., 2004).

2.2. Polymer Matrix

The polymer matrix is a critical component in transdermal patches as it holds the drug and controls its release. Numerous polymers can be used, each offering unique properties to suit different drug delivery needs. Examples of polymers commonly used in transdermal patches include:

- Polyethylene Glycol (PEG): Known for its flexibility and hydrophilicity, PEG is widely used to enhance drug solubility and release rates.
- Polyvinyl Alcohol (PVA): This polymer is valued for its film-forming properties and biocompatibility.
- Ethyl Cellulose (EC): Used for its controlled release capabilities and water-insolubility, making it ideal for sustained release formulations.
- Hydroxypropyl Methylcellulose (HPMC): Offers excellent film-forming properties and controlled drug release.
- Polyvinylpyrrolidone (PVP): Known for its good adhesion and ability to form clear, flexible films.
- Polyurethane (PU): Provides durability and elasticity, suitable for patches that need to conform to body movements.
- Eudragit: A range of copolymers (e.g., Eudragit RS, RL) used for their pH-dependent release properties.
- Chitosan: A natural polymer with excellent biocompatibility and film-forming properties.
- Sodium Alginate: Often used for its gel-forming ability and biocompatibility.
- Polyacrylic Acid (Carbomer): Provides excellent adhesive properties and controlled release.
- Polycaprolactone (PCL): A biodegradable polymer used for long-term drug delivery applications.
- Polyethylene Oxide (PEO): Known for its hydrophilicity and controlled release capabilities.
- Gelatin: A natural polymer used for its film-forming properties and biocompatibility.
- Starch Derivatives: Such as hydroxyethyl starch, used for their biocompatibility and film-forming abilities.
- Cellulose Acetate Phthalate (CAP): Used for enteric coating and controlled release applications.
- Polylactic Acid (PLA): A biodegradable polymer often used in combination with other polymers for controlled release.
- Polyglycolic Acid (PGA): Known for its biodegradability and use in sustained release formulations.
- Polylactic-co-glycolic Acid (PLGA): A copolymer used for its biodegradability and controlled release properties.
- Xanthan Gum: A natural polymer used for its thickening and stabilizing properties.
- Pectin: Used for its gel-forming abilities and biocompatibility.
- Acrylate Copolymers: Such as those used in Duro-Tak adhesives, known for their strong adhesion and controlled release.
- Polysiloxanes (Silicone Elastomers): Used for their flexibility, durability, and biocompatibility.
- Polyisobutylene (PIB): Known for its excellent adhesive properties and stability.
- Polyvinyl Acetate (PVAc): Offers good adhesion and film-forming properties.
- Polyvinyl Alcohol-co-Ethylene (EVAL): Used for its oxygen barrier properties and controlled release.
- Collagen: A natural polymer used for its biocompatibility and ability to form films.
- Polyurethane Hydrogel: Combines the properties of hydrogels with the durability of polyurethane.
- Hydroxyethyl Cellulose (HEC): Used for its thickening and film-forming properties.
- Methyl Methacrylate Copolymer: Known for its film-forming properties and controlled release.
- Poly-N-vinyl Acetamide (PNVA): Offers biocompatibility and controlled release capabilities (Kydonieus, 2017).

2.3. Permeation Enhancers

Permeation enhancers are substances that increase the skin's permeability, facilitating drug absorption. Common enhancers include:

- Alcohols (e.g., ethanol)
- Fatty acids (e.g., oleic acid)
- Surfactants (e.g., sodium lauryl sulfate) (Cevc, 2004).

2.4. Adhesives

Adhesives are crucial for ensuring the patch adheres to the skin. Commonly used adhesives include:

- Acrylate-based adhesives
- Silicone-based adhesives
- Polyisobutylene-based adhesives (Patel & Patel, 2019).

2.5. Backing Layer

The backing layer provides structural support and protects the patch from environmental factors. It is typically made from:

- Polyester films
- Aluminum foil laminates (Patel et al., 2011).

2.6. Release Liners

Release liners protect the adhesive layer and are removed before patch application. They are usually composed of:

- Silicone-coated paper
- Polyethylene-coated paper (Sharma et al., 2012).

3. Development Process: Steps in Developing a Transdermal Patch from Concept to Market

The development of a transdermal patch involves several critical steps from initial concept to market release:

3.1. Preformulation Studies

Preformulation studies involve characterizing the physicochemical properties of the drug, including solubility, stability, and compatibility with excipients (Gupta & Mishra, 2018).

3.2. Formulation Development

Formulation development includes selecting appropriate excipients, optimizing the drug load, and determining the ideal composition of the patch. This step involves extensive testing and optimization to achieve the desired drug release profile (Singh & Sharma, 2017).

3.3. Prototype Development

Prototypes of the transdermal patch are developed and tested for various parameters, including adhesion, flexibility, and drug release kinetics. Initial in vitro studies using Franz diffusion cells are conducted to evaluate drug permeation (Sharma & Sharma, 2018).

3.4. *In Vivo* Studies

In vivo studies are performed on animal models to assess the pharmacokinetics and pharmacodynamics of the drug. These studies help to understand the drug's absorption, distribution, metabolism, and excretion (ADME) profile (Kumar & Thakur, 2019).

3.5. Clinical Trials

Clinical trials are conducted in multiple phases to evaluate the safety, efficacy, and pharmacokinetics of the transdermal patch in humans. This step is crucial for obtaining regulatory approval (Patel et al., 2011).

3.6. Regulatory Approval

Regulatory approval involves submitting detailed data from preclinical and clinical studies to regulatory bodies such as the FDA or EMA for review. Approval is granted based on the safety, efficacy, and quality of the transdermal patch (Verma & Garg, 2017).

3.7. Scale-up and Manufacturing

Once regulatory approval is obtained, the transdermal patch is scaled up for commercial manufacturing. This step involves optimizing the manufacturing process to ensure consistent product quality and meeting Good Manufacturing Practices (GMP) (Patel & Patel, 2017).

3.8. Market Launch

The final step involves launching the transdermal patch in the market. This includes marketing, distribution, and post-market surveillance to monitor the product's performance and safety in the real world (Singh & Jain, 2013).

4. Challenges: Common Challenges in Formulation

Despite their advantages, the formulation and development of transdermal patches face several challenges:

4.1. Skin Barrier

The stratum corneum, the outermost layer of the skin, poses a significant barrier to drug penetration. This challenge is addressed by using permeation enhancers and physical techniques such as microneedles and iontophoresis (Lane, 2013).

4.2. Drug Properties

Not all drugs are suitable for transdermal delivery. Drugs with high molecular weight or poor lipophilicity may not penetrate the skin effectively. Formulation scientists address this challenge by modifying the drug's chemical structure or using prodrugs (Rautio et al., 2008).

4.3. Adhesion

Ensuring that the patch adheres well to the skin is crucial for effective drug delivery. Poor adhesion can lead to patch detachment and inconsistent drug release. This challenge is addressed by optimizing the adhesive formulation and using high-quality backing materials (Wokovich et al., 2006).

4.4. Stability

The stability of the drug and the patch formulation during storage is critical. Factors such as temperature, humidity, and light exposure can affect stability. This challenge is addressed by incorporating stabilizers and using protective packaging (Sharma & Jain, 2017).

4.5. Patient Variability

Variability in skin properties among patients, such as age, ethnicity, and skin condition, can affect drug absorption. This challenge is addressed by conducting extensive clinical trials to understand the impact of patient variability and developing flexible dosing regimens (Patel & Patel, 2017).

4.6. Regulatory Hurdles

Navigating the regulatory landscape can be challenging due to stringent requirements for safety, efficacy, and quality. This challenge is addressed by conducting thorough preclinical and clinical studies and maintaining compliance with regulatory guidelines (Reddy & Guy, 2010).

5. Conclusion

The formulation and development of transdermal patches involve a complex interplay of various components and processes. Understanding the key components and materials used in formulation, the steps involved in development, and the common challenges faced can enhance the efficiency and effectiveness of transdermal drug delivery systems. Ongoing research and innovation are crucial for overcoming these challenges and expanding the therapeutic potential of transdermal patches.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Reddy, M. B., & Guy, R. H. (2010). Transdermal drug delivery. In *Encyclopedia of Pharmaceutical Science and Technology* (4th ed., pp. 3653-3672). CRC Press.

[2] Sharma, R., & Rajput, M. (2018). Formulation and development of transdermal patches of clonidine hydrochloride: In vitro and *in vivo* evaluation. *Journal of Pharmacy and Bioallied Sciences, 10*(1), 20-28.

[3] Barry, B. W. (2001). Novel mechanisms and devices to enable successful transdermal drug delivery. *European Journal of Pharmaceutical Sciences, 14*(2), 101-114.

[4] Benson, H. A. E. (2005). Transdermal drug delivery: Penetration enhancement techniques. *Current Drug Delivery, 2*(1), 23-33.

[5] Flynn, G. L. (1996). Cutaneous and transdermal delivery: Processes and systems of delivery. In *Drug Delivery Systems* (pp. 143-190). CRC Press.

[6] Paudel, K. S., Milewski, M., Swadley, C. L., Brogden, N. K., Ghosh, P., & Stinchcomb, A. L. (2010). Challenges and opportunities in dermal/transdermal delivery. *Therapeutic Delivery, 1*(1), 109-131.

[7] Chien, Y. W. (1992). *Transdermal drug delivery and delivery systems*. In Novel Drug Delivery Systems (pp. 301-380). CRC Press.

[8] Gupta, J., Nandhini, C., Kumar, A. S., & Tharun, M. (2012). Formulation and evaluation of transdermal patches containing glibenclamide and atenolol. *Journal of Applied Pharmaceutical Science, 2*(1), 195-198.

[9] Ramsay, N. A., & Faulkner, A. (2013). Hormone replacement therapy: An overview. *Journal of Clinical Pharmacy and Therapeutics, 38*(4), 315-322.

[10] Patel, M., & Patel, N. (2019). Formulation and evaluation of transdermal patches of ketotifen fumarate. *International Journal of Pharmaceutical Sciences and Research, 10*(1), 34-42.

[11] Wiedersberg, S., & Guy, R. H. (2014). Transdermal drug delivery: 30+ years of war and still fighting! *Journal of Controlled Release, 190*, 150-156.

[12] Patel, D., Naik, S., & Misra, A. (2011). Advances in transdermal drug delivery. *Journal of Controlled Release, 140*(2), 95-107.

[13] Karande, P., Jain, A., & Mitragotri, S. (2004). Discovery of transdermal penetration enhancers by high-throughput screening. *Nature Biotechnology, 22*(2), 192-197.

[14] Kydonieus, A. F. (2017). *Treatise on controlled drug delivery: Fundamentals, optimization, applications*. CRC Press.

[15] Cevc, G. (2004). Lipid vesicles and other colloids as drug carriers on the skin. *Advanced Drug Delivery Reviews, 56*(5), 675-711.

[16] Gupta, S., & Mishra, A. (2018). Development and characterization of transdermal patches of propranolol hydrochloride. *Asian Journal of Pharmaceutical and Clinical Research, 11*(1), 56-64.

[17] Singh, B., & Sharma, V. (2017). Formulation and evaluation of transdermal patches of losartan potassium. *International Journal of Pharmaceutical Sciences Review and Research, 46*(1), 102-108.

[18] Kumar, D., & Thakur, G. (2019). Preparation and evaluation of transdermal patches of diclofenac sodium. *Journal of Pharmaceutical Sciences and Research, 11*(2), 455-463.

[19] Verma, R., & Garg, S. (2017). Development of transdermal patches of tramadol hydrochloride. *International Journal of Drug Development and Research, 9*(3), 67-75.

[20] Choudhary, N., & Sharma, P. (2018). Formulation and evaluation of transdermal patches of atenolol. *Journal of Drug Delivery and Therapeutics, 8*(4), 55-62.

[21] Patel, H., & Patel, G. (2017). Development and evaluation of transdermal patches of risperidone. *Asian Journal of Pharmaceutics, 11*(1), 57-64.

[22] Singh, M., & Patel, G. (2011). Formulation and evaluation of transdermal patches of atenolol and losartan potassium. *Journal of Applied Pharmaceutical Science, 1*(8), 96-101.

[23] Sharma, N., & Sharma, P. K. (2012). Formulation and evaluation of transdermal patches of glipizide. *International Journal of Pharmaceutical Sciences Review and Research, 14*(1), 20-27.

[24] Singh, R., & Gupta, R. (2011). Formulation and evaluation of transdermal patches of zolpidem tartrate. *Journal of Applied Pharmaceutical Science, 1*(8), 68-73.

[25] Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., & Savolainen, J. (2008). Prodrugs: Design and clinical applications. *Nature Reviews Drug Discovery, 7*(3), 255-270.

[26] Wokovich, A. M., Prodduturi, S., Doub, W. H., Hussain, A. S., & Buhse, L. F. (2006). Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy, and quality attribute. *European Journal of Pharmaceutics and Biopharmaceutics, 64*(1), 1-8.

[27] Lane, M. E. (2013). Skin penetration enhancers. *International Journal of Pharmaceutics, 447*(1-2), 12-21.

[28] Sharma, N., & Parikh, R. K. (2011). Formulation and evaluation of transdermal patches of metformin hydrochloride. *International Journal of Pharmaceutical Sciences Review and Research, 7*(2), 142-147.

[29] Sharma, R., & Sahu, R. (2011). Formulation and evaluation of transdermal patches of diclofenac sodium. *International Journal of Pharmaceutical Sciences Review and Research, 7*(2), 144-150.

[30] Sharma, N., & Chauhan, M. (2012). Formulation and evaluation of transdermal patches of aceclofenac. *International Journal of Pharmaceutical Sciences Review and Research, 15*(1), 1-7.

[31] Patel, R. P., & Patel, G. (2012). Formulation and evaluation of transdermal patch of meloxicam. *International Journal of Drug Development and Research, 4*(1), 38-47.

[32] Sharma, N., & Khatri, S. (2012). Formulation and evaluation of transdermal patches of ketotifen fumarate. *International Journal of Pharmaceutical Sciences Review and Research, 13*(2), 18-24.

[33] Patel, D., & Patel, N. (2011). Formulation and evaluation of transdermal patches of telmisartan. *Journal of Applied Pharmaceutical Science, 1*(8), 24-30.

[34] Singh, V., & Jain, S. (2013). Formulation and evaluation of transdermal patches of atenolol and losartan potassium. *Journal of Applied Pharmaceutical Science, 2*(2), 59-64.

[35] Sharma, N., & Jain, S. K. (2010). Formulation and evaluation of transdermal patches of candesartan cilexetil. *International Journal of Pharmaceutical Sciences Review and Research, 7*(1), 13-18.